These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 27079164

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
    Woodruff S, Feugère G, Abreu P, Heissler J, Ruiz MT, Jen F.
    J Thromb Thrombolysis; 2016 Nov; 42(4):494-504. PubMed ID: 27344439
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study.
    Martinez C, Wallenhorst C, Rietbrock S, Freedman B.
    J Am Heart Assoc; 2020 Jan 21; 9(2):e014376. PubMed ID: 31937194
    [Abstract] [Full Text] [Related]

  • 7. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE, Cavallazzi R.
    PLoS One; 2015 Jan 21; 10(11):e0143252. PubMed ID: 26587983
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
    Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, Gallus A, Lecumberri R, Molnar S, Ageno W, Le Gal G, Falanga A, Hulegårdh E, Ranta S, Kamphuisen P, Debourdeau P, Rigamonti V, Ortel TL, Lee A.
    J Thromb Haemost; 2015 Jun 21; 13(6):1010-8. PubMed ID: 25851122
    [Abstract] [Full Text] [Related]

  • 10. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
    Eischer L, Kammer M, Traby L, Kyrle PA, Eichinger S.
    J Thromb Haemost; 2017 Jul 21; 15(7):1368-1374. PubMed ID: 28407356
    [Abstract] [Full Text] [Related]

  • 11. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
    Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, Fernández-Capitán C, Nieto JA, Barillari G, Bertoletti L, Monreal M, RIETE investigators.
    Am J Med; 2018 Apr 21; 131(4):430-437. PubMed ID: 29274307
    [Abstract] [Full Text] [Related]

  • 12. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism.
    Tripodi A, Legnani C, Lemma L, Cosmi B, Palareti G, Chantarangkul V, Mannucci PM.
    J Thromb Thrombolysis; 2010 Aug 21; 30(2):215-9. PubMed ID: 20419336
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
    Martinez C, Katholing A, Folkerts K, Rietbrock S.
    Curr Med Res Opin; 2018 Nov 21; 34(11):1985-1990. PubMed ID: 29798688
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT.
    BMC Health Serv Res; 2017 Jan 23; 17(1):74. PubMed ID: 28114939
    [Abstract] [Full Text] [Related]

  • 16. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
    Mai V, Bertoletti L, Cucherat M, Jardel S, Grange C, Provencher S, Lega JC.
    PLoS One; 2019 Jan 23; 14(4):e0214134. PubMed ID: 30933993
    [Abstract] [Full Text] [Related]

  • 17. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    den Exter PL, Hooijer J, van der Hulle T, van Oosten JP, Dekkers OM, Klok FA, Huisman MV.
    Thromb Haemost; 2017 Nov 01; 117(11):2163-2167. PubMed ID: 28981552
    [Abstract] [Full Text] [Related]

  • 18. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Noel-Savina E, Sanchez O, Descourt R, André M, Leroyer C, Meyer G, Couturaud F.
    Thromb Res; 2015 Jan 01; 135(1):78-83. PubMed ID: 25466839
    [Abstract] [Full Text] [Related]

  • 19. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism.
    Bryk AH, Piróg M, Plens K, Undas A.
    Vascul Pharmacol; 2016 Dec 01; 87():242-247. PubMed ID: 27865826
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.